[1] [1] CORTESE B, GRANADA J F, SCHELLER B, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document[J]. Eur Heart J, 2016, 37(14): 1096-1103.

[2] [2] ABOYANS V, RICCO J B, BARTELINK M E L, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS)[J]. Rev Esp Cardiol (Engl Ed), 2018, 71(2): 111.

[3] [3] ENZMANN F K, NIERLICH P, MANUELA A, et al. Nitinol stent versus bypass in long femoropopliteal lesions: 2-year results of a randomized controlled trial[J]. JACC: Cardiovasc Interv, 2019, 12(24): 2541-2549.

[5] [5] LAMMER J, ZELLER T, HAUSEGGER K A, et al. Sustained benefit at 2 Years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial[J]. CardioVascular Interv Radiol, 2015, 38(1): 25-32.

[6] [6] TSAI S, LIU Y L, HOANG L, et al. Comparative outcomes of interventions for femoropopliteal chronic total occlusion versus non-chronic total occlusion lesions from the multicenter XLPAD registry[J]. J Am Heart Assoc, 2023, 12(12): e028425.

[7] [7] MICARI A, NERLA R, VADAL G, et al. 2-year results of paclitaxel-coated balloons for long femoropopliteal artery disease[J]. JACC Cardiovasc Interv, 2017, 10(7): 728-734.

[8] [8] TEPE G, SCHNORR B, ALBRECHT T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons[J]. JACC Cardiovasc Interv, 2015, 8(1): 102-108.

[9] [9] D'ORIA M, BERCHIOLLI R, GARGIULO M, et al. Bypass vs endovascular treatment for occluded femoropopliteal stents in patients with critical limb-threatening ischemia[J]. J Vase Surg, 2023, 78(5): 1270-1277.

[10] [10] ENZMANN F K, NIERLICH P, HLZENBEIN T, et al. Vein bypass versus nitinol stent in long femoropopliteal lesions: 4-year results of a randomized controlled trial[J]. Ann Surg, 2023, 277(6): e1208-e1214.

[11] [11] SCHILLINGER M, SABETI S, LOEWE C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery[J]. N Engl J Med, 2006, 354(18): 1879-1888

[12] [12] KOECKERLING D, RAGUINDIN P F, KASTRATI L, et al. Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis[J]. Eur Heart J, 2023, 44(11): 935-950.

[13] [13] TOSAKA A, SOGA Y, IIDA O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting[J]. J Am Coll Cardiol, 2012, 59(1): 16-23.

[16] [16] BAUSBACK Y, WITTIG T, SCHMIDT A, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease[J]. J Am Coll Cardiol, 2019, 73(6): 667-679.

[17] [17] RYMER J A, ANTONIO GUTIERREZ J. Drug-coated balloons with or without provisional bare metal stenting in femoropopliteal disease: No metal left behind?[J]. Circ Cardiovasc Interv, 2024, 17(2): e013847.